вторник, 19 июля 2016 г.

Novartis Says Profit May Drop on Entresto Spending, Gleevec

Novartis Says Profit May Drop on Entresto Spending, Gleevec


Novartis AG said profit may fall this year as the Swiss drugmaker increases spending on the heart medicine Entresto and faces declining sales of its best-selling cancer treatment Gleevec. Core operating income will either be about the same as 2015 or decline by a percentage in the low single digits at constant exchange rates, Novartis said Tuesday in a statement.



from Biotech News